APRIL AYERS JEFF GIBBERMAN MELISSA HSU EL-KAMARYA SS, SHARDELLA MD, ABDEL-HAMID M, ET AL. A RANDOMIZED CONTROLLED TRIAL TO ASSESS THE SAFETY AND EFFICACY.

Slides:



Advertisements
Similar presentations
Bias in Clinical Trials
Advertisements

Rare Film Guide Slide Set. Clinical Trial Design for Pirfenidone Study Purpose of Study: To see if the use of pirfenidone decreases the loss of lung function.
New England Journal of Medicine October 18;367: Relapse Risk after Discontinuation of Risperidone in Alzheimer’s disease Molly Moncrieff.
Randomised Clinical Trial: Lactobacillus reuteri DSM vs. Placebo in Children With Acute Diarrohea Aliment Pharmacol Ther 2012:36 (4): R. Francavilla.
The Bahrain Branch of the UK Cochrane Centre In Collaboration with Reyada Training & Management Consultancy, Dubai-UAE Cochrane Collaboration and Systematic.
The Cochrane Reviews of Acupuncture Doris Hubbs, MD, FACP April 26, 2013.
J OURNAL C LUB : T HE R ANDOMIZED C ONTROLLED T RIAL July 10 th, 2008 Rakhi Naik, MD.
BROOKLYN 2 RADIOTHERAPY Patries HERST Sat 31 st Aug 2013 Session 1 / Talk 1 09:20 – 09:46 ABSTRACT Purpose. Acute radiation-induced cystitis is a common.
Are topical NSAIDs a safe and effective treatment for Corneal Abrasions? Department of Emergency Medicine University of Pennsylvania Health System Andrew.
TMC125 Safety and Tolerability: 24-week Results of the Pooled DUET-1 and -2 Trials R Haubrich, M Schechter, S Walmsley, M Peeters, M Janssens, G De Smedt.
St John’s wort for major depression (Review) Linde, Berner & Kriston (2008/9)
Journal Club Alcohol and Health: Current Evidence November-December 2005.
Journal Club Alcohol and Health: Current Evidence January-February 2006.
Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Nebulized Hypertonic Saline for Bronchiolitis Florin TA, Shaw KN, Kittick M, Yakscoe.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2015.
Hep 202 Just when you thought you knew everything.
1 Informative Studies of New Therapeutic Agents in Major Depression, GAD & Panic W Z Potter, M.D., PhD. Merck Research Laboratories.
Effect of Hepatic Impairment on Sorafenib Pharmacokinetics: Results of a Multicenter, Open-Label, Single-Dose, Phase I Trial J Lettieri, A Mazzu,
Rapivab™ - peramivir injection
Slide 1 EZT 2002-W-6022-SS Ezetimibe Co-administered with Statins: Efficacy and Tolerability Copyright © 2003 MSP Singapore Company, LLC. All rights reserved.
Systematic Reviews.
Interventions for nausea and vomiting in early pregnancy: a Cochrane Review Clinical
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Placebo-Controls in Short-Term Clinical Trials of Hypertension Sana Al-Khatib, MD, MHS Assistant Professor of Medicine Division of Cardiology Duke University.
Should developing countries continue to use older drugs for essential hypertension? A prescription survey in South Africa suggested that prescribers were.
A randomized, double-blinded, placebo-controlled study of the effect of a combination of lemon verbena extract and fish oil omega-3 fatty acid on joint.
Efficacy, Hematologic Effects and Dose of Ruxolitinib in Myelofibrosis Patients with Low Platelet Starting Counts ( x 10 9 /L): A Comparison to Patients.
Efficacy and Tolerability of the Diclofenac Epolamine Patch in the Treatment of Minor Soft Tissue Injury W Carr, P Beks, C Jones, S Rovati, M Magelli,
Efficacy and Safety of Maraviroc in Treatment- Experienced (TE) Patients Infected with R5 HIV-1: 96-week Combined Analysis of the MOTIVATE 1 & 2 Studies.
C-BR- 1 Raptiva ™ (efalizumab) Benefit:Risk Assessment Charles Johnson, MB, ChB Senior Director Head of Specialty Biotherapeutics Genentech, Inc.
Acute Rhinitis. Results Yakoot, M., Amel, S. (2011). Efficacy and safety of a multiherbal formula with vitamin C and zinc (Immumax) in the management.
OFEV ® (nintedanib) safety Safety data INPULSIS ® -1 & -2 These slides are provided by Boehringer Ingelheim for medical to medical education only. Last.
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
INPULSIS® trial design and baseline characteristics
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
How to Maintain a Healthy Liver R.T. Clement, MD Richard Clement Nutrition
EVALUATING u After retrieving the literature, you have to evaluate or critically appraise the evidence for its validity and applicability to your patient.
Angelo L Gaffo Kenneth G Saag Core Evidence 2009:4 25–36
Copyright © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 18 Systematic Review and Meta-Analysis.
Lab # 2 Liver Function Tests (LFTs) ALT&AST T.A. Bahiya M. Osrah.
Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.
From: PLOS Neglected Tropical DiseaseJanuary 2014 Presented by Pavitra Charoensrisakkul and Peeraya Permkarnjaroen 3 rd year medical cadet Phramongkutklao.
Efficacy of Colchicine When Added to Traditional Anti- Inflammatory Therapy in the Treatment of Pericarditis Efficacy of Colchicine When Added to Traditional.
Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
Telbivudine Versus Lamivudine in Chinese Patients with Chronic Hepatitis B: Results at 1 Year of a Randomized, Double-Blind Trial HEPATOLOGY 2008;47:
Phase 3 Treatment-Naïve and Treatment-Experienced
Dr. Iram Shad PGT-Medicine MU-1, HFH,RWP
Effects of Uric acid- lowering therapy on renal outcomes: a systematic review and meta-analysis Nephrol Dial Transplant (2014) 29: Vaughan Washco.
Copyright © 2012 American Medical Association. All rights reserved.
James M. Roberts, M.D., Leslie Myatt, Ph.D.,et al.
Phase 3 Treatment-Naïve and Treatment-Experienced
Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2
A presentation to: Meeting name Date
Hepatic Encephalopathy protocol - EMB review
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
Phase 2 Treatment Naïve Injection Drug Use
Phase 3 Treatment Naïve HIV Coinfection
Tolerability of Isoniazid Preventive therapy Among HIV infected Cohort in Nigeria Folajinmi Oluwasina Strategic Information Unit AIDS Healthcare Foundation,
Chen S, Dong Y, Kiuchi MG, et al
Just when you thought you knew everything.
Treatments for Subacute Cough in Primary Care: Systematic Review and Meta-analyses of Randomized Clinical Trials Benjamin Speich, Anja Thomer, Soheila.
Leber B et al. Proc ASH 2013;Abstract 94.
PRESENTER: Quynh vu, pgy-2
Guideline for the Treatment of Alcohol Use Disorder in the Outpatient Setting with Intramuscular Naltrexone Assess Candidacy for IM Naltrexone Meets DMS-V.
Phase 3 Treatment-Naïve and Treatment-Experienced
Kelly Schatzlein PA-S and Keely Tietjen PA-S
Pei-Yuan Su,Yu-Chun Hsu,Shun-Sheng Wu,Wei-Wen Su,Maw-Soan Soon
Medical Scientific Experts
Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2
Presentation transcript:

APRIL AYERS JEFF GIBBERMAN MELISSA HSU EL-KAMARYA SS, SHARDELLA MD, ABDEL-HAMID M, ET AL. A RANDOMIZED CONTROLLED TRIAL TO ASSESS THE SAFETY AND EFFICACY OF SILYMARIN ON SYMPTOMS, SIGNS AND BIOMARKERS OF ACUTE HEPATITIS. PHYTOMEDICINE 2009: (16) 391–400 Journal Club: A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis

To determine if the bioactive extract of milk thistle, silymarin, reduces the signs, symptoms, and biomarkers of acute hepatitis. Purpose

Double blind, randomized, placebo-controlled study 105 patients from two hospitals in Egypt Criteria  Alanine aminotransferase (ALT) level of more than 2.5 times the upper limit of normal (>100 IU/L)  Jaundice/scleral icterus  At least three additional symptoms of acute hepatitis Methods

Two study groups:  Vitamin placebo  140 mg of silymarin Treatment: 3x/day for 4 weeks Data collected:  Demographic information  Signs and symptoms  Adverse events/side effects  Laboratory tests  Alanine aminotransferase (ALT)  Aspartate aminotransferase (AST)  Direct and total bilirubin Methods (continued)

Impaired biliary excretion - silymarin group had a significantly faster resolution of symptoms compared to the placebo group  Dark urine, jaundice, and scleral icterus - significant indicators  Clay-colored stool and direct bilirubin – not significant Hepatocellular damage and systemic effects of liver inflammation - no significant difference between the two treatment groups Results

Weakness:  Lack of improvement in objective biomarkers, such as ALT, AST, and indirect and direct bilirubin  Pill treatment compliance Strength:  Demonstrated the safety of silymarin supplementation for acute hepatitis patients  no serious adverse events were recorded  side effects were similar in frequency in both the silymarin and placebo groups  diarrhea was rare and not more frequent in the silymarin group Strength/Weakness

Standard recommended doses of silymarin are safe and may be potentially effective in improving the symptoms of acute clinical hepatitis despite lack of a detectable effect on biomarkers of the underlying hepatocellular inflammatory process Conclusion

Background Milk thistle has been used medicinally for over 2,000 years, mainly to treat hepatic and biliary disorders. Silymarin is a flavonoid complex that can be extracted from the seeds of milk thistle and is thought to be the biologically active component.

Database Overview The study we chose to review looked at various forms of viral hepatitis while the databases, with the exception of Natural Standard, focused more on hepatitis B and C.

The Natural Standard Database Gives silymarin an evidence grade of C for acute viral hepatitis. Many of the studies reviewed were seen as methodologically weak, including; heterogeneous patient populations, small sample sizes, large drop out rates, and concomitant alcohol abuse. Also effects were seen as small insignificant. Gathered information from 211 sources.

Natural Medicine Comprehensive Database Insufficient evidence to rate whether milk thistle is a beneficial treatment for hepatitis B and C. There is some report of patients feeling better, but objective measures show no improvement.

Cochran Database A meta analysis found a lack of high quality evidence to support milk thistle as an intervention for viral hepatitis.

Up to Date Database Small studies have yielded conflicting results in terms of milk thistle’s effectiveness in treating hepatitis C and chronic liver disease. Conflict may be due to lack of standardization in preparation. It is stated that herbal preparations are essentially unregulated in the United States. It should be noted that the reviewed study took place in Egypt.

Database Conclusions Overall the information from these databases is comparable to the reviewed study where improvements seen with milk thistle treatment were subjective and considered “soft”. There was no significant reduction in the relevant biomarkers. It is inconclusive whether milk thistle is an effective treatment for viral hepatitis.

References El-Kamarya SS, Shardella MD, Abdel-Hamid M, Ismail S, El-Ateek M, Metwally M, Mikhail N, Hashem M, Mousa A, Aboul-Fotouh A, El-Kassas M, Esmat G, Strickland GT. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. Phytomedicine. 2009;16: 391–400. Natural Standard Database – The Authority on Integrative Medicine. Foods, Herbs & Supplements Database: Silymarin. Updated June 1, Accessed June 1, Natural Medicine Comprehensive Database – Unbiased, Scientific Clinical Information on Cemplemetary, Alternative, and Integrative Therapies. Milk Thistle. =ND&pt=100&id=138&fs=ND&searchid= Updated June 1, Accessed June 2, =ND&pt=100&id=138&fs=ND&searchid= Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD DOI: / CD pub3. UpToDate Database – an evidence based, peer reviewed information resource. Tai AW, Chung RT. Investigational therapies for hepatitis C virus infection. therapies-for-hepatitis-c-virus-infection?source=search_result&search=milk+thistle&selectedTitle=2~9. Updated April 17, Accessed June 2, therapies-for-hepatitis-c-virus-infection?source=search_result&search=milk+thistle&selectedTitle=2~9